← All trials
NCT04646044
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 13, 2020
- Primary completion
- Jan 28, 2021
- Completion date
- Mar 27, 2021
- First posted
- Nov 27, 2020
- Last posted
- Nov 27, 2020
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nektar TherapeuticsLead sponsor
- Nektar TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.